OCT-980
/ Octant
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 27, 2026
Octant Receives FDA Orphan Drug Designation for OCT-980 for the Treatment of Retinitis Pigmentosa
(Businesswire)
- "It is currently being evaluated in a Phase 1/2 clinical study."
Orphan drug • Retinitis Pigmentosa
1 to 1
Of
1
Go to page
1